As a result, monoclonal antibodies against EGFR aim to downregulate its overexpression; cetuximab is currently the only FDA-approved anti-EGFR agent used for HNC treatment, whereas panitumumab, another EGFR-specific antibody, is under clinical evaluation for its effectiveness in patients with advanced HNSCC [218]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.